The prognosis of dilated cardiomyopathy due to hypertension (HT-DCM) is surprisingly unknown, particularly in the absence of coronary disease and diabetes. We aimed at investigating the long-term outcome and the predictors of mortality in patients with left ventricular systolic dysfunction exclusively due to hypertension. From October 1995 to May 2001, 90 consecutive patients with echocardiographic fractional shortening (FS) o30% and 29 control patients with FS X30% were included. Obstructive coronary disease was excluded by dipyridamole myocardial perfusion imaging in all patients and coronary angiography in 60. After a mean follow-up of 4.371.6 years, the total mortality rate of HT-DCM was twice as much higher than that of patients without left ventricular systolic dysfunction (P ¼ 0.01). In HT-DCM, the 5-year mortality rate was 26%. Univariate analyses selected age and creatinine for being positively related to mortality, and body mass index, FS and blood pressure during follow-up for being negatively related to mortality. Neither the improvement of left ventricular FS nor the decrease in left ventricular mass index was related to survival. Multivariate analysis identified (hazard ratio; 95% confidence interval) age (1.08; 1.02-1.13), body mass index (0.86; 0.75-0.98), and baseline FS (0.88; 0.78-0.98) as independent predictors of mortality. In conclusion, poor survival in HT-DCM can be anticipated by the severity of left ventricular systolic dysfunction and advanced age. Instead of ominous signs, high blood pressure and body mass may predict a more favourable prognosis.
Introduction
Left ventricular hypertrophy has been recognized as a blood pressure-independent risk factor for cardiovascular morbidity and mortality in patients with systemic hypertension. 1 The role of hypertrophy in explaining the increased number of cardiovascular events may be accounted for cardiac mass either representing a surrogate of hypertensive vascular disease or an early marker of myocardial dysfunction. 2 In the first case, hypertrophy explains the increased mortality due to myocardial infarction and stroke, while in the second it explains the mortality that results from heart failure and perhaps a number of cases of sudden death.
Presently, heart failure has become one of the most important causes of disability and death in the Western societies 3 and hypertension is thought to represent one of its chief contributing factors. To date, only a few studies have looked at specific underlying causes of myocardial dysfunction with regard to the clinical prognosis. 4 The majority of reports categorized patients according to the diagnosis of ischaemic or nonischaemic disease, 5 while hypertension has been examined merely as a potentially interfering risk factor.
Even though the benefits of antihypertensive treatment on the prevention of heart failure have been demonstrated in the past, 6 being indeed more successful than in preventing either stroke or coronary heart disease, 7 little is known about the prognosis of established left ventricular systolic dysfunction. It also remains undetermined whether or not changes in left ventricular systolic function might alter the prognosis in this particular setting of patients.
The aim of this study was to investigate the longterm prognosis of patients with hypertensive heart disease characterized by poor left ventricular systolic function. We also aimed at identifying clinical and cardiac potential markers of mortality.
Methods

Study population
Between October 1995 and May 2001, two groups were studied: (1) fractional shortening (FS) o30%, constituted of 90 consecutive patients with hypertension and heart failure due to left ventricular systolic dysfunction and (2) FS X30%, constituted of 29 patients with preserved left ventricular systolic function, who served as controls. Left ventricular systolic dysfunction was defined based on echocardiographic FS.
Patients received regular medical care at the Hypertension Unit of the Instituto do Coração, Hospital das Clínicas, University of São Paulo, which is a tertiary Medical Center.
Inclusion criteria were history of hypertension and at least two documented blood pressure measurements 4140/90 mmHg on previous medical recordings. Exclusion criteria were diabetes mellitus, chronic angina, history or ECG evidence of myocardial infarction, valvular heart disease, Chagas' disease or any other condition that might potentially affect cardiac structure and function other than systemic hypertension.
Renovascular disease was excluded in all patients by 99m Tc-DTPA scintigraphy and/or abdominal MRI angiography exams followed by digital aortography in 17 patients.
Clinical investigation
Before enrollment, patients underwent complete clinical and biochemical evaluations.
Smoking was defined by current or past consumption of X5 cigarettes per day for at least 5 years.
Three blood pressure estimates were computed: (1) the casual blood pressure at enrollment, (2) the mean of the two maximum measurements and (3) the mean of the two minimum measurements recorded during the first 2 years of follow-up.
Weight and height were measured to calculate body mass index (BMI ¼ weight Â height À2 ), which was used to categorize patients as normal (BMIp25 kg/m 2 ), overweight (25oBMIp30 kg/m 2 ) or obese (BMI430 kg/m 2 ). Electrocardiographic left ventricular hypertrophy and strain were established based on the presence of voltage criteria SV1 þ RV543.5 mV and ST depression X0.05 mV associated to T-wave inversion X0.1 mV in leads I, aVL and V5 or V6.
Ecocardiographic investigation
M-mode two-dimensionally guided echocardiograms were obtained using an ALOKA SSD 870 equipment with 2.5 and 3.5 MHz transducers. The following parameters were determined, based on the recommendations of the American Society of Echocardiography: 8 In addition, left ventricular ejection fraction was correspondingly calculated based on left ventricular end-diastolic and end-systolic volumes.
11
Coronary artery disease investigation
Obstructive coronary disease was additionally examined by means of planar dypiridamole 99m Tcsestamibi myocardial scintigraphy, further complemented with coronary angiography in 60 patients after informed consent, including 28 of 45 patients with normal myocardial perfusion. Only patients with o50% luminal stenosis affecting either one of the three major epicardial coronary arteries or their first order branches were included.
Follow-up
Follow-up was undertaken until August 2003 and included routine medical examinations performed at 3-month intervals for clinical assessment and adjustment of therapy. Antihypertensive treatment consisted basically of hydrochlorothiazide (25-50 mg per day), followed by methyldopa (500-1500 mg per day) and then by captopril (50-150 mg per day), enalapril (10-40 mg per day) or hydralazine (100-200 mg per day). At the author's discretion and according to renal function, patients also received digoxin (0.125-0.25 mg per day) and spironolactone (25-100 mg per day).
The contemplated end point was mortality from any cause. The causes of death were determined from the hospital medical recordings and autopsy reports or from death certificates and interviews with patients' relatives.
All procedures were carried out in accordance with our institutional guidelines and the protocol was approved by our institutional Ethics Committee.
Statistical analysis
Data are expressed as mean7s.d. and as percentages. Student's t-test, Mann-Whitney rank sum test, Fisher exact test and w 2 test were used for group comparisons. Intragroup comparisons of repetitive variables were performed using the paired Student's t-test and the Wilcoxon signed-rank test. Survival curves were estimated by the Kaplan-Meier method. The log-rank test was used for statistical comparisons between the survival probability curves of each of the following qualitative variables: gender, white or non-white ethnical background, smoking, heart failure NYHA functional class, electrocardiographic left ventricular hypertrophy and strain, bundle branch block, atrial fibrillation, and echocardiographically documented moderate to severe mitral regurgitation.
The Wald statistic tested for the association of survival times with the following continuous variables: age, body mass index, blood pressure, haemoglobin, sodium, potassium, creatinine, cholesterol, echocardiographic left ventricular internal dimensions, posterior wall thickness, relative wall thickness, mass index and FS.
Multivariate survival analysis was performed with the Cox proportional hazards model to determine which variables were independently associated with mortality. The variables chosen for entering the model were those with Po0.05 in the univariate model. The stepwise selection method was used considering as significant the P-value of 0.05 to remove a variable from or to enter it into the model. Results are expressed as hazard ratios with 95% confidence intervals.
All analyses were conducted using the SAS software (Statistical Analysis System, version 8.0).
Results
The clinical characteristics of the two groups studied accordingly to the presence or absence of left ventricular systolic dysfunction are depicted in Table 1 . There were differences in gender, heart failure functional class, ECG changes, serum creatinine and sodium, body mass index and blood pressure, in addition to expected differences in echocardiographic parameters. All but four patients with preserved left ventricular systolic function had mass index 4125 g/m 2 .
Survival according to left ventricular systolic dysfunction
Five patients were lost to follow-up and were thus censored at the time of their last clinical visit, which took place 8 to 65 months after enrollment. After a mean follow-up of 4.371.6 years, the total mortality rate of patients in FS o30% group was significantly higher than that of patients in FS X30% group (23 vs 10%, log-rank P ¼ 0.01).
The causes of death were heart failure (6), sudden death (8), stroke (3), myocardial infarction (3) and noncardiovascular or unknown (4). All deaths from heart failure and sudden deaths occurred in the group with FS o30%. In seven of the 11 patients dying suddenly or of myocardial infarction, including a patient with preserved left ventricular systolic function, the diagnosis of ischaemic heart disease had been previously excluded by coronary angiography.
Predictors of mortality in hypertensive cardiomyopathy
The clinical and echocardiographic variables investigated for potentially interfering with the long-term survival of patients with FS o30% are depicted in Table 2 . The mean time of follow-up was 4.871.3 years, ranging from 0.7 to 7.2 years, in the survivor cohort, whereas the mean time from enrollment to death was 2.271.3 years, ranging from 0.1 to 4.2 years.
Univariate analyses demonstrated age and creatinine to be positively associated and FS to be negatively associated with mortality (parameter estimate: 0.046, 0.755 and À0.1092, respectively). Interestingly, body mass index, cholesterol as well as maximum and minimum diastolic blood pressure during follow-up were negatively associated with mortality (parameter estimate: À0.13463, À0.02808, À0.0628 and À0.0480, respectively). Outcome of hypertensive cardiomyopathy C de Carvalho Frimm et al A subgroup constituted of 54 patients had also a second echocardiographic exam 23714 months after enrollment (range: 6-62 months). As depicted in Table 3 , while left ventricular mass index did not change, FS increased and was accompanied by a mild but significant decrease in ventricular internal dimension, resulting in a significant increase in relative wall thickness. In all, 25 patients had 410% increase and eight had complete restoration of FS. None of the echocardiographic changes were statistically associated with patients' outcome.
Multivariate analysis identified age (hazard ratio: 1.08; 95% CI: 1.02-1.13; P ¼ 0.003), body mass index (hazard ratio: 0.86; 95% CI: 0.75-0.98; P ¼ 0.02) and FS at enrollment (hazard ratio: 0.88; 95% CI: 0.78-0.98; P ¼ 0.02) as independent predictors of mortality. Cholesterol was not entered into the multivariate analysis because of the great number of cases with missing values who ultimately died (nine in 11).
The outcomes of patients according to body mass index, FS and a classification of patients based on a composite of the severity of left ventricular systolic dysfunction (FSp15.2 vs 415.2) with body mass index (normal vs overweight/obese) are represented in Figure 1 . The outcome was worse in patients with normal body mass than in obese patients as well as in patients in the lowest quartile of fractional shortening distribution. The association of normal body mass and severe left ventricular systolic dysfunction showed the worst outcome represented by a 5-year mortality rate of 100%, as compared with a mortality rate of less than 35% observed in overweight/obese patients, irrespective of the severity of left ventricular systolic dysfunction, and in patients with normal BMI without severe left ventricular systolic dysfunction.
Discussion
The present study confirms the previous presumption that left ventricular systolic dysfunction adversely affects the prognosis in hypertension. Age, BMI and the severity of FS impairment were identified as independent predictors of mortality. The response of left ventricular systolic function to antihypertensive treatment, although positive in as many as 46% of patients, had no substantial impact on survival. Interestingly, both cholesterol and follow-up blood pressure showed an inverse statistical association with mortality.
To date, this is the first study to exclude atherosclerotic coronary artery disease as a cause of cardiomyopathy in hypertension. Hypertension and coronary disease are imputed as leading causes of heart failure. 3 In fact, both conditions often occur together 3 and other concurrent diseases such as diabetes may also coexist. It has been estimated that as much as 30-50% of hypertensive patients who progress to heart failure have myocardial infarction. 12 In the present study, 16 patients were excluded for having been diagnosed concurrent diabetes mellitus at enrollment. Seven of these patients died on follow-up. Apart from diabetes being a potential cause of left ventricular systolic dysfunction, if these patients were included, the risk of cardiovascular mortality would be overestimated.
The prevalence of hypertensive cardiomyopathy is likely to be decreasing in response to the preventive impact of antihypertensive treatment. 
Outcome of hypertensive cardiomyopathy C de Carvalho Frimm et al
The present cohort of little less than a hundred patients was assembled from a total of 1200 patients, the majority of them with moderate to severe hypertension, receiving regular treatment in a tertiary medical center of a large metropolitan area. In addition to this relatively small prevalence in the hypertensive population, the present findings indicate that the long-term prognosis is better than in other forms of dilated cardiomyopathy. 5 The 5-year survival rate of 74% we observed contrasts with rates of only 25-38% reported by the Framingham study, 3 but corroborates with the absence of mortality over 3 years of follow-up in a small group of patients with hypertensive cardiomyopathy. 13 Since the majority of patients who died suddenly or of myocardial infarction were documented to be free from obstructive coronary disease at entry, left ventricular systolic dysfunction might presumably represent a marker of ensuing coronary disease. Whether this presumptive risk encompasses or surpasses that already settled for left ventricular hypertrophy 14, 15 remains undetermined. In a previous study, in which hypertensive patients with and without cardiac dysfunction were unrestrictedly included, left ventricular hypertrophy predicted cardiovascular mortality irrespective of cardiac function and rhythm disturbances. 16 We also learned that left ventricular systolic dysfunction is amenable to restoration in a great number of patients following chronic antihypertensive treatment 17 and speculated whether the improvement in left ventricular systolic function might favourably affect the prognosis in a likewise manner already evident for idiopathic cardiomyopathy. 18, 19 The present findings, however, argued against this hypothesis. Neither changes in fractional shortening nor in ventricular mass accounted for a better prognosis. It may be that the observed changes were not of enough magnitude or resulted from minor vascular remodelling to translate into a measurable benefit on survival. As a matter of fact, the benefits of reverse remodelling are still debated even for hypertensive patients with preserved left ventricular systolic function. [20] [21] [22] In contrast to what is commonly documented in the general population, 23, 24 obese patients with hypertensive cardiomyopathy had the best prognosis. The conceivable negative influence of body weight in cardiac pump performance 25, 26 has been recently challenged by the finding of normal or even enhanced left ventricular systolic function concurrent with obesity, especially in its early stages. 27 It appears that obesity confers a better outcome for heart failure, irrespective of the type of cardiomyopathy. 28 On the other hand, the association between cachexia and advanced heart failure is well recog- Outcome of hypertensive cardiomyopathy C de Carvalho Frimm et al nized and wasting usually identifies patients with a poor prognosis. 29 Our patients did not report significant weight loss and only four were actually underweight (body mass index o20 g/m 2 ) at entry. Therefore, although proinflammatory cytokines were not measured, cachexia seems unlikely to explain the negative influence of normal body mass in survival.
The paradoxical effects of cholesterol and blood pressure may share similar mechanisms attributable to body mass and represent a phenomenon now recognized as reverse epidemiology. 30 In heart failure, high levels of blood pressure 31 as well as the magnitude of cardiac power, a composite measure of ejection fraction and blood pressure, were shown to be strong predictors of survival. 32 The present findings indicate that reverse epidemiology also occurs in heart failure due to hypertensive cardiomyopathy and may help to identify patients with a better prognosis.
Study limitations
In Brazil, a country composed of a variety of ethnical cultures, it is very difficult to establish a definite racial background for the individual. Based on external physical characteristics alone, we found non-white patients to represent about 50% of the population studied. On the one hand, this finding may stand for the well-known higher incidence of heart failure and myocardial dysfunction in black subjects when compared with white subjects, a fact that has been attributed to a higher prevalence of long-standing undertreated hypertension in black subjects. 33 On the other hand, the presence of a great number of non-white patients in the present study may be accounted for the higher prevalence of people with African origin among the Brazilian population. Whatever the case, caution must be made when extending the present findings to other countries, particularly those in which the prevalence of black individuals is known to be much lower.
The distinct antihypertensive strategy of controlling blood pressure using methyldopa as the adrenergic inhibitor instead of a beta-blocker represents the difficulty of a satisfactory blood pressure response to this last class of drug in the population we studied. 34 We realize that African patients may indeed benefit from beta-blocker therapy for heart failure, 35 but certainly not at the expense of an insufficient control of hypertension.
Although this study has demonstrated that left ventricular systolic dysfunction is in fact an independent determinant of a poorer prognosis in hypertension, the lack of data regarding diastolic function certainly represents a shortcoming. Recently, the prognosis of heart failure due to diastolic dysfunction has been reported to be comparable to that of patients with left ventricular systolic dysfunction, 36 in apparent contradiction with previous findings. 37 In patients with left ventricular systolic dysfunction, the presence of diastolic dysfunction assessed by mitral inflow and pulmonary venous flow patterns has been demonstrated to be a reliable prognostic marker. [38] [39] [40] In addition, mitral annulus velocity estimated by tissue Doppler may identify patients with pulmonary congestion and, therefore, with an immediate poorer prognosis. 41 The importance of diastolic dysfunction in patients with hypertensive dilated cardiomyopathy remains to be investigated.
Clinical implications
To date, the prognosis of dilated cardiomyopathy of exclusively hypertensive origin has not been conclusively established. The current findings indicate the possibility of a more favourable long-term outcome in these patients than that currently recognized for patients with ischaemic and idiopathic dilated cardiomyopathy. This possibility should be taken into account when planning therapeutic strategies aimed at improving the survival of patients with hypertension and heart failure. In these patients, the severity of left ventricular systolic dysfunction may represent a surrogate end point to survival, but its actual value has yet to be investigated in comparison with other forms of cardiomyopathy. The clinical prognosis of hypertensive dilated cardiomyopathy is also influenced by reverse epidemiology. In consequence, among other implications regarding body mass and cholesterol levels, easy blood pressure control must not necessarily be viewed as a favourable clinical response, since instead it may represent a more advanced degree of left ventricular systolic dysfunction. Alternatively, because of the high prevalence of hypertension in the general population, it is conceivable that a number of patients with different causes of cardiomyopathy might have been included in this study. This could be especially the case of patients with less severe hypertension to account for the degree of left ventricular systolic dysfunction. In these patients, easy blood pressure control can thus represent a marker of a diverse cause of left ventricular systolic dysfunction other than hypertension with an anticipated poorer prognosis. 
